122 related articles for article (PubMed ID: 38336274)
1. Identification and validation of KIF23 as a hypoxia-regulated lactate metabolism-related oncogene in uterine corpus endometrial carcinoma.
Wang T; Peng X; Liu W; Ji M; Sun J
Life Sci; 2024 Mar; 341():122490. PubMed ID: 38336274
[TBL] [Abstract][Full Text] [Related]
2. Development and validation of a novel DNA damage repair-related long non-coding RNA signature in predicting prognosis, immunity, and drug sensitivity in uterine corpus endometrial carcinoma.
Wang T; Ji M; Liu W; Sun J
Comput Struct Biotechnol J; 2023; 21():4944-4959. PubMed ID: 37876625
[TBL] [Abstract][Full Text] [Related]
3. Lactate metabolism-related genes to predict the clinical outcome and molecular characteristics of endometrial cancer.
Shi R; Li H; Wei S; Yu Z; Zhang J; Zhang Q; Zhou T; Yao Y; Zhang Q; Zhang T; Wang H
BMC Cancer; 2023 May; 23(1):491. PubMed ID: 37259038
[TBL] [Abstract][Full Text] [Related]
4. Prognostic signature construction and immunotherapy response analysis for Uterine Corpus Endometrial Carcinoma based on cuproptosis-related lncRNAs.
Zhang X; Ye Z; Xiao G; He T
Comput Biol Med; 2023 Jun; 159():106905. PubMed ID: 37060773
[TBL] [Abstract][Full Text] [Related]
5. Integrated bioinformatics analysis and experimental validation reveals fatty acid metabolism-related prognostic signature and immune responses for uterine corpus endometrial carcinoma.
Guo C; He Y; Chen L; Li Y; Wang Y; Bao Y; Zeng N; Jiang F; Zhou H; Zhang L
Front Oncol; 2022; 12():1030246. PubMed ID: 36439473
[TBL] [Abstract][Full Text] [Related]
6. Identification and Validation of Cuproptosis-Related Prognostic Signature and Associated Regulatory Axis in Uterine Corpus Endometrial Carcinoma.
Chen Y
Front Genet; 2022; 13():912037. PubMed ID: 35937995
[No Abstract] [Full Text] [Related]
7. m
Fang F; Wang P; Huang H; Ye M; Liu X; Li Q
BMC Cancer; 2022 Dec; 22(1):1364. PubMed ID: 36581816
[TBL] [Abstract][Full Text] [Related]
8. Identification of an endoplasmic reticulum stress-related gene signature to predict prognosis and potential drugs of uterine corpus endometrial cancer.
Zhou P; Wu C; Ma C; Luo T; Yuan J; Zhou P; Wei Z
Math Biosci Eng; 2023 Jan; 20(2):4018-4039. PubMed ID: 36899615
[TBL] [Abstract][Full Text] [Related]
9. KDM4B, a potential prognostic biomarker revealed by large-scale public databases and clinical samples in uterine corpus endometrial carcinoma.
Zhang M; Liu Y; Hou S; Wang Y; Wang C; Yin Y; Chen X
Mol Omics; 2022 Jul; 18(6):506-519. PubMed ID: 35485290
[TBL] [Abstract][Full Text] [Related]
10. Construction of N-7 methylguanine-related mRNA prognostic model in uterine corpus endometrial carcinoma based on multi-omics data and immune-related analysis.
Zhao J; Zou J; Jiao W; Lin L; Wang J; Lin Z
Sci Rep; 2022 Nov; 12(1):18813. PubMed ID: 36335189
[TBL] [Abstract][Full Text] [Related]
11. Cuproptosis-Associated lncRNA Gene Signature Establishes New Prognostic Profile and Predicts Immunotherapy Response in Endometrial Carcinoma.
Jiang XY; Hu JJ; Wang R; Zhang WY; Jin QQ; Yang YT; Mei J; Hong L; Yao H; Tao F; Li JJ; Liu Y; Zhang L; Chen SX; Chen G; Song Y; Zhou SG
Biochem Genet; 2023 Dec; ():. PubMed ID: 38108937
[TBL] [Abstract][Full Text] [Related]
12. Development of an Oxidative Phosphorylation-Related and Immune Microenvironment Prognostic Signature in Uterine Corpus Endometrial Carcinoma.
Liu J; Chen T; Yang M; Zhong Z; Ni S; Yang S; Shao F; Cai L; Bai J; Yu H
Front Cell Dev Biol; 2021; 9():753004. PubMed ID: 34901000
[No Abstract] [Full Text] [Related]
13. Identification and validation of oxeiptosis-associated lncRNAs and prognosis-related signature genes to predict the immune status in uterine corpus endometrial carcinoma.
Niu L; Wu Z
Aging (Albany NY); 2023 May; 15(10):4236-4252. PubMed ID: 37211398
[TBL] [Abstract][Full Text] [Related]
14. Integrated analysis of tumor mutation burden and immune infiltrates in endometrial cancer.
Zhou H; Chen L; Lei Y; Li T; Li H; Cheng X
Curr Probl Cancer; 2021 Apr; 45(2):100660. PubMed ID: 33012523
[TBL] [Abstract][Full Text] [Related]
15. FAT2 mutation is associated with better prognosis and responsiveness to immunotherapy in uterine corpus endometrial carcinoma.
Wang Z; Xing L; Huang Y; Han P
Cancer Med; 2023 Feb; 12(3):3797-3811. PubMed ID: 36812126
[TBL] [Abstract][Full Text] [Related]
16. Identification of an immune gene signature for predicting the prognosis of patients with uterine corpus endometrial carcinoma.
Zhou C; Li C; Yan F; Zheng Y
Cancer Cell Int; 2020 Nov; 20(1):541. PubMed ID: 33292199
[TBL] [Abstract][Full Text] [Related]
17. An miRNA signature associated with tumor mutation burden in endometrial cancer.
Zhou H; Chen L; Qin M; Lei Y; Li T; Li H; Cheng X
Biosci Rep; 2020 Nov; 40(11):. PubMed ID: 33141168
[TBL] [Abstract][Full Text] [Related]
18. Identification of an Immune-Related LncRNA Prognostic Signature in Uterine Corpus Endometrial Carcinoma Patients.
Sun XX; Wen HQ; Zhan BX; Yang P
Clin Lab; 2021 Nov; 67(11):. PubMed ID: 34758230
[TBL] [Abstract][Full Text] [Related]
19. Identification of an integrated kinase-related prognostic gene signature associated with tumor immune microenvironment in human uterine corpus endometrial carcinoma.
Wei S; Zhang J; Shi R; Yu Z; Chen X; Wang H
Front Oncol; 2022; 12():944000. PubMed ID: 36158685
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive Analysis of Prognosis and Immune Landscapes Based on Lipid-Metabolism- and Ferroptosis-Associated Signature in Uterine Corpus Endometrial Carcinoma.
Yang P; Lu J; Zhang P; Zhang S
Diagnostics (Basel); 2023 Feb; 13(5):. PubMed ID: 36900015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
